Pharmex AS
Score · fiscal year 2025
65of 100
How to read this: the company is ahead of 79 % of companies in the Morning class Small in the same sector in 2025. What does this mean?
Rank in the Morning class Small: 1,561 of 7,414 · What are Morning company classes?
Place in the whole sector: 4,779 of 22,952 · Handel
Profile
Cheetah · Sprinter
High profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 97 and solidity 47 out of 100 among companies in the Morning class Small in the same sector in 2025. Methodology
Against the sector
Pharmex AS is 14 points above the median for companies in the Morning class Small in the same sector in 2025.
Median score 51 among 7,414 companies.
Against companies in the Morning class Small in the same sector in 2025: operating margin 27.0% (median 3.4%) and equity ratio 35.4% (median 36.3%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 42 MNOK | 20 MNOK |
| Operating margin | 27.0% | 3.4% |
| Profit margin | 25.8% | 3.0% |
| Return on assets | 49.8% | 10.0% |
| Equity ratio | 35.4% | 36.3% |
| Debt-to-equity | 1.82 | 1.51 |
| Current ratio | 1.56 | 1.73 |
| Revenue growth | 25.8% | 5.7% |
The median and “ahead of” refer to companies in the Morning class Small in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 65, Pharmex AS does better than 79% of companies in the Morning class Small in the same sector (7,414 companies) in 2025.
Score 2023–2025
- Pharmex AS
- Median: companies in the Morning class Small in the same sector
Pharmex AS has a score of 65 for 2025, rank 4,779 of 22,952 in the sector.
Strongest: Profitability: percentile 97 against peers, operating margin 27.0% against a median of 3.4%. Growth: percentile 83 against peers, revenue growth 25.8% against a median of 5.7%.
Weakest: Consistency: percentile 38 against peers.
Worth a closer look
- What lies behind weak consistency, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
Pharmex AS had an operating margin of 27.0% and an equity ratio of 35.4% in 2025, and ranks 4,779 of 22,952 in Handel.
From 2024 to 2025: the operating margin rose from 19.3% to 27.0% and the equity ratio fell from 52.3% to 35.4%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 8 MNOK and 101 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 84 MNOK |
| EV/EBIT | 8.0 | 101 MNOK |
| P/B | 1.0 | 8 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 7.2% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 97 | weight 30% |
|---|---|---|
| Solidity | 47 | weight 25% |
| Liquidity | 43 | weight 15% |
| Growth | 83 | weight 15% |
| Consistency | 38 | weight 15% |
Durability: 75 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is Pharmex AS?
The operating margin was 27.0% in 2025, against a median of 3.4% among companies in the Morning class Small in the same sector. Return on assets was 49.8%.
How solid is Pharmex AS?
The equity ratio was 35.4% in 2025 (median 36.3%). Debt-to-equity was 1.82 (median 1.51).
What is the liquidity of Pharmex AS like?
The current ratio was 1.56 in 2025 (median 1.73).
How does Pharmex AS compare in Handel?
Pharmex AS ranks 4,779 of 22,952 in Handel for 2025. Among companies in the Morning class Small it is number 1,561 of 7,414. Revenue changed by 25.8% from the year before.
From the Central Coordinating Register
- Org. no.
- 981070968
- Legal form
- AS
- Sector
- Handel (46.460)
- Morning company class
- Small
- Employees
- 0–4 (not registered)
- Founded
- 1 September 1999 27 years in operation
- Share capital
- 0.60 MNOK
- Business address
- Nordlysveien 41, 0489 OSLO
- Municipality
- Oslo rank 63–220 of 357 in Norway
- Latest accounts filed
- 2025
- Website
- www.pharmex.no
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 28 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 85 | 76 | 65 | |
| Rank | 1,139 | 1,562 | 4,779 | |
| Operating margin | 13.0% | 19.3% | 27.0% | |
| Return on assets | 40.1% | 45.9% | 49.8% | |
| Equity ratio | 63.1% | 52.3% | 35.4% | |
| Current ratio | 2.87 | 2.15 | 1.56 | |
| Revenue growth | – | 34.1% | 25.8% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 24.8 MNOK | 33.2 MNOK | 41.8 MNOK |
| Operating profit | 3.2 MNOK | 6.4 MNOK | 11.3 MNOK |
| Profit before tax | 3.6 MNOK | 6.6 MNOK | 10.8 MNOK |
| Net profit | 2.8 MNOK | 5.2 MNOK | 8.4 MNOK |
| Financial expenses | 0.8 MNOK | 0.4 MNOK | 1.1 MNOK |
| Total assets | 10.9 MNOK | 15.4 MNOK | 24.0 MNOK |
| Current assets | 10.9 MNOK | 15.4 MNOK | 24.0 MNOK |
| Equity | 6.9 MNOK | 8.1 MNOK | 8.5 MNOK |
| Retained earnings | 6.3 MNOK | 7.5 MNOK | 7.9 MNOK |
| Total liabilities | 4.0 MNOK | 7.3 MNOK | 15.5 MNOK |
| Current liabilities | 3.8 MNOK | 7.2 MNOK | 15.3 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 6492549.
Further
Similar companies
- Høitomt Auto AS index 65, rank 4,775 · compare
- Auto Bilnett AS index 65, rank 4,776 · compare
- Sunde Handel AS index 65, rank 4,780 · compare
- El-Tunet Håvardstun Elektriske AS index 65, rank 4,782 · compare
- Norway Designs AS index 65, rank 4,784 · compare